FDA GLP-1 Compounding Enforcement 2026: Distributor Compliance

FDA GLP-1 Compounding Enforcement: What Wholesale Distributors Need to Know About 2026 Compliance

FDA announced January 2025 that semaglutide and tirzepatide remain on the drug shortage list through Q2 2025, but signals accelerated enforcement against unlicensed compounders beginning in 2026. Wholesale distributors supplying active pharmaceutical ingredients (APIs) to compounding pharmacies face expanded liability for downstream use verification under 21 USC 353b and state pharmacy board enforcement actions targeting the supply chain.

Regulatory Context

The Federal Food, Drug, and Cosmetic Act Section 503B establishes requirements for outsourcing facilities that compound sterile drugs. Under 21 USC 353b(a)(1), these facilities must register with FDA, comply with current good manufacturing practice (cGMP) requirements under 21 CFR Parts 210 and 211, and report adverse events.

During a declared drug shortage, FDA exercises enforcement discretion under Section 503A, allowing state-licensed pharmacies to compound drugs appearing on FDA's shortage list without 503B registration. This discretion applies to semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) while the shortage persists.

State boards of pharmacy regulate traditional compounding pharmacies under Section 503A. These entities may compound patient-specific prescriptions but cannot engage in manufacturing-scale production. API sourcing requirements vary by state, but most require pharmacies to obtain bulk substances from FDA-registered facilities.

Key Details

FDA's January 2025 statement indicates semaglutide and tirzepatide will remain on the shortage list until approximately June 2025. Once removed, the agency will reinstate standard enforcement of 21 USC 353b against compounders operating without 503B registration.

The enforcement timeline creates a compliance cliff for the GLP-1 compounding market. Entities compounding these drugs without 503B status after shortage resolution face:

• Warning letters under 21 USC 331(a) for introducing unapproved drugs into interstate commerce
• Injunctions under 21 USC 332 to cease compounding operations
• Seizure actions under 21 USC 334 for adulterated or misbranded drugs
• State pharmacy board disciplinary action for exceeding traditional compounding scope

FDA has issued 14 warning letters to GLP-1 compounders since November 2023, primarily targeting entities making unsubstantiated drug claims or operating beyond 503A scope limits. The agency's 2026 enforcement priority shifts from marketing violations to manufacturing status verification.

Wholesale distributors supplying semaglutide or tirzepatide APIs must verify purchaser status before June 2025. Under 21 CFR 210.3(b)(16), only FDA-registered outsourcing facilities (503B) or licensed pharmacies operating within 503A limits may purchase bulk drug substances for compounding.

State boards of pharmacy in California, Texas, Florida, and Ohio have initiated enforcement actions against pharmacies receiving APIs from unlicensed sources. California Business and Professions Code Section 4127.1 requires pharmacies to obtain drugs only from licensed wholesalers. Texas Administrative Code 22 TAC 291.17 imposes similar sourcing restrictions.

Impact Assessment for Wholesale Distributors

Distributors holding wholesale drug licenses under state pharmacy statutes face direct compliance obligations:

API sourcing verification: Before distributing semaglutide or tirzepatide APIs after June 2025, distributors must confirm purchaser holds either active FDA 503B registration or state pharmacy license with traditional compounding authority. This requires checking FDA's Outsourcing Facility Database and state board licensure records.

Distribution records: Under 21 CFR 205.50(a), wholesale distributors must maintain pedigree records showing each prior sale, purchase, or trade of a prescription drug. API sales to unlicensed compounders create liability exposure if those entities face subsequent enforcement action.

State license conditions: Many state wholesale drug distributor licenses prohibit sales to unlicensed entities. Violations trigger administrative action by state boards of pharmacy, including license suspension under statutes like Ohio Revised Code 4729.57.

DSCSA implications: While APIs are currently excluded from Drug Supply Chain Security Act tracing requirements under 21 USC 360eee-1(3)(A), state-level pedigree requirements still apply. Distributors selling to entities later determined to be operating illegally may face challenges documenting legitimate supply chain participation during audits.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs, of which 1,234 hold active FDA registration. The remaining 41 entities operate under state wholesale licenses without FDA establishment registration — a status incompatible with API distribution to compounding pharmacies under 21 CFR 207.

The average compliance score across all tracked entities is 51/100, placing most distributors in the "Fair" tier. Only 28 entities (2.2%) achieve "Excellent" scores above 80, while 47 entities score below 40 ("Poor" or "Minimal" tiers). Distributors in lower tiers typically lack NABP accreditation or hold licenses in fewer than 10 states, signals of limited operational infrastructure for verifying downstream purchaser status.

Only 63 entities in the directory hold NABP Verified-Accredited Wholesale Distributors (VAWD) accreditation. NABP's accreditation criteria under VAWD Standard 3.2 require distributors to verify purchaser licensure before each transaction. This operational framework directly supports GLP-1 API sourcing compliance, but represents less than 5% of tracked entities.

73 entities have at least one FDA recall on record. While most recalls involve temperature excursions or labeling errors rather than unlicensed distribution, the presence of enforcement history indicates heightened FDA scrutiny during audits.

Practical Guidance for Compliance Teams

Verify API supplier status before June 2025: Use the ColdChainCheck directory to confirm your GLP-1 API supplier holds active FDA registration. Filter by "FDA Registration" data field. Entities without registration cannot legally distribute APIs to compounding pharmacies after the shortage ends.

Cross-reference NABP accreditation: Distributors with VAWD accreditation maintain documented purchaser verification processes. Search the directory for VAWD-accredited entities if your current supplier lacks this credential. The accreditation signals operational readiness for post-shortage compliance requirements.

Review downstream purchaser licenses: If you operate as a distributor, audit all entities purchasing semaglutide or tirzepatide APIs. Check FDA's Outsourcing Facility Database for 503B registrations. For 503A pharmacy purchasers, verify state pharmacy board licenses and confirm no prior enforcement actions for exceeding compounding scope.

Monitor state enforcement trends: ColdChainCheck tracks state-level compliance signals including license suspensions and board actions. California, Texas, Florida, and Ohio have initiated pharmacy board investigations targeting unlicensed compounding. Review entity records in these jurisdictions for recent disciplinary activity.

For comprehensive guidance on wholesale distributor compliance requirements, see ColdChainCheck's regulatory guides covering state licensure, FDA registration, and NABP accreditation standards.

Disclaimer: This article provides informational content based on publicly available regulatory data and is not legal or compliance advice. Consult your legal counsel and regulatory affairs team to assess your specific obligations under federal and state law.